| 证券代码：002626 | 证券简称：金达威 | 公告编号：2026-015 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司关于 2026 年度 与中牧实业股份有限公司日常经营关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 2026 年 2 月 3 日召开的厦门金达威集团股份有限公司（以下简称"公司"） 第九届董事会第十一次会议以 7 票同意，0 票反对，0 票弃权的表决结果审议通 过《关于 2026 年度与中牧实业股份有限公司日常经营关联交易预计的议案》， 同意公司（含子公司）与中牧实业股份有限公司（以下简称"中牧股份"）及其 所属子公司 2026 年度日常经营关联交易预计销售金额不超过 3,100.00 万元、采 购金额不超过 100.00 万元。关联董事顾卫华先生、徐肖特先生回避表决。 该议案在公司董事会审批权限范围之内，无需提交公司股东会审议。 （三）上一年度日常关联交易实际发生情况 关联交易 类 ...

厦门金达威集团股份有限公司 第九届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：002626 | 证券简称：金达威 | 公告编号：2026-014 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 经与会董事认真审议，本次会议以现场结合通讯表决的方式审议通过了以下 议案： 厦门金达威集团股份有限公司（以下简称"公司"）第九届董事会第十一次 会议于 2026 年 2 月 3 日在厦门市海沧区公司五层会议室以现场结合通讯表决的 方式召开。本次会议通知已于 2026 年 1 月 30 日以通讯方式发出，并获全体董事 确认。本次会议由公司董事长江斌先生主持，公司董事会成员应到九人，实际参 会人数九人。公司副总经理、财务总监、董事会秘书等高级管理人员亦列席了本 次会议。本次会议的召集、召开符合《中华人民共和国公司法》和公司章程的有 关规定。 一、 会议以 7 票同意、0 票反对、0 票弃权的表决结果审议通过《关于 2026 年度与中牧实业股份有限公司日常经营关联交易预计的议 ...

厦门金达威集团股份有限公司 | 证券代码：002626 | 证券简称：金达威 | 公告编号：2026-013 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 关于"金威转债"回售的第三次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 风险提示：投资者选择回售等同于以 100.044 元/张（含息税）卖出持有的 "金威转债"。截至本公告之日，"金威转债"的收盘价格高于本次回售价格， 投资者选择回售可能会带来损失，敬请投资者注意风险。 厦门金达威集团股份有限公司（以下简称"公司"）于 2026 年 1 月 8 日召 开的第九届董事会第十次会议，2026 年 1 月 26 日召开的 2026 年第一次临时股 东会、2026 年第一次债券持有人会议，审议通过了《关于变更部分募集资金投 资项目的议案》。根据《厦门金达威集团股份有限公司向不特定对象发行可转换 公司债券募集说明书》（以下简称"《募集说明书》"）的约定，"金威转债" 的附加回售条款生效，现将"金威转债"回售有关事项公告如下： 一、 ...

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2026-012 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于签署募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）近日与中信银行股份有 限公司厦门分行（以下简称"中信银行厦门分行"）及广发证券股份有限公司（以 下简称"广发证券"）重新签署了《募集资金三方监管协议》，具体情况如下： 一、 募集资金基本情况 经中国证券监督管理委员会《关于同意厦门金达威集团股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2024〕1567 号）同意， 公司向不特定对象发行面值总额 129,239.48 万元可转换公司债券，期限 6 年，每 张面值为人民币 100 元，发行数量 12,923,948 张，募集资金总额为人民币 1,292,394,800.00 元。扣除保荐承销费、专项审计及验资费、律师费等发行费用 （不含增值税）共计人民币 ...

Core Viewpoint - Jindawei's stock performance shows a slight decline, with a focus on financing and margin trading activities indicating low investor confidence and liquidity levels [1][2]. Financing Summary - On January 30, Jindawei's financing buy amount was 6.85 million yuan, while the financing repayment was 11.31 million yuan, resulting in a net financing outflow of 4.46 million yuan [1]. - The total financing and margin trading balance for Jindawei as of January 30 was 442 million yuan, which represents 3.81% of its market capitalization and is below the 50th percentile level over the past year, indicating a low financing balance [1]. - In terms of margin trading, Jindawei had a margin repayment of 100 shares and no shares sold on January 30, with a remaining margin balance of 14,270 yuan, also below the 20th percentile level over the past year [1]. Company Performance Summary - As of September 30, Jindawei reported a total revenue of 2.604 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 11.16% [2]. - The net profit attributable to shareholders for the same period was 361 million yuan, showing a significant year-on-year increase of 63.47% [2]. - Jindawei has distributed a total of 2.761 billion yuan in dividends since its A-share listing, with 488 million yuan distributed over the past three years [2]. Shareholder and Institutional Holdings Summary - As of September 30, Jindawei had 36,300 shareholders, a decrease of 10.95% from the previous period, while the average number of circulating shares per person increased by 12.29% to 16,817 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [2]. - The Southern CSI 1000 ETF and Huaxia CSI 1000 ETF are also among the top ten shareholders, with slight changes in their holdings [2].

Investment Rating - The report suggests a positive investment outlook for the liquor and food sectors, particularly highlighting the potential for growth during the upcoming Spring Festival season [1][2]. Core Insights - The report emphasizes the initiation of the Spring Festival peak season for liquor sales, with leading brands like Moutai showing significant improvements in sales and pricing, indicating a recovery in market sentiment and expectations [1][2]. - In the food sector, there is an anticipated boost in demand due to pre-holiday stocking, with specific focus on snack foods and beverages as key growth areas [1][2]. Summary by Sections Liquor Sector - The report indicates that the liquor market is entering a peak season, with Moutai leading the way in sales and price recovery, driven by increased demand and channel reforms [2]. - Other notable brands such as Guizhou Moutai, Ancient Well, and Luzhou Laojiao are recommended for short-term investment due to their strong performance and market positioning [1]. Food Sector - The food sector is expected to benefit from pre-holiday stocking, with companies like Anjuke and Qiaqia Foods positioned to capitalize on the festive demand [2][4]. - Anjuke is focusing on new product launches and expanding into overseas markets, while Qiaqia Foods is set to improve profitability in 2026 due to lower raw material costs [4][3]. Growth Opportunities - The report identifies growth opportunities in the snack and beverage segments, with specific companies such as H&H International Holdings and Nongfu Spring highlighted for their potential [1][2]. - The emphasis is placed on the recovery of the restaurant and dairy sectors, with companies like Yili and Qingdao Beer expected to show positive performance [1][2].

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial application, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor of NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can quickly elevate NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4][6]. Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse reactions [6][7]. Natural Sources and Supplementation - Natural food sources of NMN are limited, making NMN supplements, which can provide up to 300 times the dietary intake, more effective for achieving beneficial doses [8]. Synthesis Technology - The NMN synthesis process has shifted from chemical methods to fully enzymatic methods, focusing on high purity, safety, and environmental sustainability [10][12]. - Leading companies are innovating in full enzymatic synthesis and patenting technologies to create competitive advantages [12]. Market Trends and Demand - The aging population and increasing anti-aging awareness among younger demographics are driving demand for NMN products, with the market expected to grow significantly [19][21]. - The NMN market in China is projected to exceed 3 billion yuan by 2025, with applications expanding beyond health supplements and cosmetics into areas like pet nutrition and agricultural technology [28][24]. Application Areas - NMN is primarily used in health supplements (90% market share) and cosmetics (10-20% market share), with potential future applications in pet nutrition, medical health, and agricultural technology [24][28]. - The Chinese health supplement market is expected to surpass 430 billion yuan by 2025, indicating substantial growth potential for NMN products [40]. Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60-70% of market share [35]. Regulatory Environment - The regulatory landscape for NMN is evolving, with significant progress in China towards legalizing NMN as a health supplement, which could reshape the market dynamics [17][61]. - The "blue hat" certification for health supplements in China represents the highest standard for product safety and compliance, which could significantly impact market structure if achieved [37]. Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and technological iterations, necessitating a focus on compliance and innovation to unlock market potential [61][63]. - Companies are encouraged to innovate their business models and extend their value chains to enhance competitiveness and market presence [66].

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2026-011 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于"金威转债"回售的第二次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 风险提示：投资者选择回售等同于以 100.044 元/张（含息税）卖出持有的 "金威转债"。截至本公告之日，"金威转债"的收盘价格高于本次回售价格， 投资者选择回售可能会带来损失，敬请投资者注意风险。 厦门金达威集团股份有限公司（以下简称"公司"）于 2026 年 1 月 8 日召 开的第九届董事会第十次会议，2026 年 1 月 26 日召开的 2026 年第一次临时股 东会、2026 年第一次债券持有人会议，审议通过了《关于变更部分募集资金投 资项目的议案》。根据《厦门金达威集团股份有限公司向不特定对象发行可转换 公司债券募集说明书》（以下简称"《募集说明书》"）的约定，"金威转债" 的附加回售条款生效，现将"金威转债"回售有关事项公告如下： 一、 ...

Group 1: Market Outlook and Product Expansion - The coenzyme Q10 market has a broad outlook, expanding from the initial target group of individuals aged 65 and above and heart disease patients to include statin users, working professionals, and athletes. Demand in overseas markets remains stable, while domestic and emerging market demand is gradually being released [2]. - The company plans to expand its production capacity based on market demand assessments and its own advantages, ensuring a leading industry position and market share [2]. - The company’s 10,000-ton oil project will produce algae oil Omega-3, DHA, and ARA, utilizing microbial fermentation technology for efficient and scalable production, which is environmentally friendly and aligns with ESG principles [3]. Group 2: Raw Material and Product Development - The company maintains R&D investments in leading products like coenzyme Q10, continuously improving technology and processes to ensure cost leadership and product quality [3]. - New market opportunities are being explored to diversify product offerings, including algae oil Omega-3, yeast protein, and biological sweeteners [3]. - The yeast protein business is gaining attention for its high nutritional value and sustainability, with plans for further R&D and production [4]. Group 3: Nutritional Supplements and Market Strategy - The company’s nutritional supplement factory in the U.S. has overcome previous losses and is expanding production capacity and product lines, including soft capsules, to meet brand demands and increase profitability [5]. - Increased regulatory scrutiny on cross-border health products is expected to eliminate low-quality products, creating a fair market environment for compliant companies [6]. - The brand strategy for 2026 focuses on expanding market share and enhancing brand influence through increased marketing investment and optimized product channels [6][7].

Core Viewpoint - The company, Kingdawei, is focusing on enhancing its brand presence and market share in the nutrition and health sector, particularly through its well-known brand, Doctor's Best, which offers popular products like Coenzyme Q10, fish oil, glucosamine, and vitamins [1] Group 1: Brand Strategy - The company has a long-standing commitment to the nutrition and health industry, with a focus on the Doctor's Best brand [1] - There will be increased attention and support for the Doctor's Best brand in the new year, particularly in China [1] - The company plans to enhance brand influence through various strategies, including increased marketing investment and optimization of product channel construction [1] Group 2: Product and Market Development - The company aims to boost sales scale and market share by developing new media channels and improving operational levels [1] - The sales of key products like Coenzyme Q10, fish oil, glucosamine, and vitamins have been growing year by year, indicating strong consumer recognition [1]